Roche Diagnostics Launches Two Cancer Drug Testing Agents In Japan
This article was originally published in PharmAsia News
Executive Summary
Roche Diagnostics plans to launch the biomarker KRASfor Merck Serono's colon cancer drug Erbitux (cetuximab) in March. KRAS will be used to test genotypes when administering colon cancer drugs to decide the relationship between genotypes and drug efficacy. The company also plans to launches EGFRtesting for lung cancer drugs this summer, which will be used to assess efficacy of AstraZeneca's Iressa (gefitinib) and Chugai's Tarceva (erlotinib). (Click here for more - Japanese language
You may also be interested in...
Behavioral Health Company Two Chairs Secures $72M In Equity And Debt Infusion
Two Chairs, which uses algorithms to match the right therapists with patients, secured $72m in investment to expand its business.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.